Clariane


Allowing for firm terms of the two capital increases: larger-than-expected dilution effect

13/06/24 -"The group has completed the first tranche of its planned recap and will launch the second one, with a deep discount (65% on the closing price as of 11/06/2024) on the subscription price but coverage ..."

Pages
53
Language
English
Published on
13/06/24
You may also be interested by these reports :
07/02/25
Supported by ongoing operational improvements, Emeis delivered FY24 results ahead of guidance and provided above-consensus FY25 guidance. While the ...

07/02/25
GN’s Q4 results met market expectations. Healthy growth in the Hearing segment was counterbalanced by a weaker performance in Gaming & Consumer and ...

07/02/25
Healthineers reported a solid performance in Q1, surpassing consensus expectations with sales up +2.1%, adjusted EBIT up +2.5%, and net profit up ...

06/02/25
Qiagen’s Q4 24 results aligned with market expectations and slightly exceeded management’s guidance. Most segments demonstrated healthy sales growth. ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO